JAMES WELSH to Neoplasms, Second Primary
This is a "connection" page, showing publications JAMES WELSH has written about Neoplasms, Second Primary.
Connection Strength
1.211
-
Five-year overall survival with ipilimumab and stereotactic ablative radiotherapy for metastatic disease. Radiother Oncol. 2023 06; 183:109618.
Score: 0.472
-
High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial. Radiother Oncol. 2021 09; 162:60-67.
Score: 0.420
-
Acute myelogenous leukemia after exposure to strontium-89 for the treatment of adenocarcinoma of the prostate. Cancer. 2000 Jul 01; 89(1):226-7.
Score: 0.098
-
Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer. JAMA Netw Open. 2018 08 03; 1(4):e181390.
Score: 0.086
-
Clinical cancer genetics. Part 2: Breast. Am J Clin Oncol. 2014 Feb; 37(1):86-9.
Score: 0.063
-
Clinical cancer genetics: Part I: Gastrointestinal. Am J Clin Oncol. 2011 Jun; 34(3):332-6.
Score: 0.052
-
Incidence of Second Malignancy after Successful Treatment of Limited-Stage Small-Cell Lung Cancer and Its Effects on Survival. J Thorac Oncol. 2017 11; 12(11):1696-1703.
Score: 0.020